The Childhood Epilepsy Panel is relevant in cases where epilepsy is the primary symptom. 25% of epilepsy cases have their debut in childhood, especially early childhood. The Childhood Epilepsy Panel includes more than 100 genes involved in the development of epilepsy with early-onset, epileptic encephalopathy, or developmental epileptic encephalopathy. 


The current version contains 110 genes.

The panel is evaluated and updated regularly. To see the full panel, click on the icon below.


The Childhood Epilepsy Panel is performed using Next Generation Sequencing (NGS), an advanced technique that offers deep, large-scale deciphering of the genome. The technique has revolutionized genetics by enabling different approaches for high-throughput, scalable sequencing.

Click on the icon for more information about NGS. 


Panels may include both coding, non-coding, and regulatory regions of the genome, sequenced to a minimum depth of 20. Any coding regions are analyzed +/- 10 base pairs from the exon-intron boundary.

The data is analyzed and annotated with our state-of-the-art in-house developed computational pipeline, integrating high-tech machine learning algorithms with industry-standard software solutions to deliver the most comprehensive data analysis. Throughout the workflow, rigorous quality control steps ensure consistent, valid, and accurate results. A plethora of professional, curated databases are integrated into our pipeline, including, but not limited to, gnomAD, ClinVar, Omim, HGMD, RefSeq, and DBSNP, ensuring high confidence variant classifications. Furthermore, several prediction tools are integrated into the variant classification, such as SIFT, PolyPhen, MutationTaster, AION, SpliceFinder, etc. All quality assessment metrics are available upon request. In case of failure to acquire data from specific genomic target regions within a panel, you will be notified.

Click on the icon for more information about BIOINFORMATICS. 


  • Blood (2-5 ml EDTA-blood)
  • DNA (minimum 3 µg)
  • Saliva (minimum 2mL)


The test is performed as data extract (virtual targeted panel) from whole exome data.


Chemistry: Twist Biosystems Human Core Exome


Hardware: Illumina Novaseq 6000 Sequencer


Data processing: An in-house bioinformatic pipeline performs variable calling and filtering calling.


Metrics: Average read depth >100-fold. On target coverage,>97% at a >20-fold read depth.


By ordering an analysis at Amplexa Genetics A/S, the requester confirms to have obtained the necessary informed consent for the performance of the requested analyses and accepts Amplexa Genetics Terms and Conditions. A hard-copy requisition or an e-mail stating the specific study together with the receipt of a sample is considered an order to conduct the analysis.


From the day of order receipt, the turnaround time is five weeks.